Sepsis Diagnostics Market Research Investigates World Market AnalysisPosted by Arslan on August 20th, 2019 According to a study by Fact.MR, the sepsis diagnostics market is expected to witness strong growth, registering 7.7% CAGR during the forecast period 2017-2026. The global sepsis diagnostics market is also projected to generate US$ 707.3 million revenue by the end of 2026. Owing to the increase in scope and applications, significant growth is expected in the market. Moreover, early detection has been shown to be crucial for the better outcome of patients suffering from sepsis. Following are the insights on how the global sepsis diagnostics market will perform in the coming years. Gram-positive bacterial sepsis segment is likely to account for the maximum share in terms of revenue in the global market for sepsis diagnostics. Gram-positive bacterial sepsis are projected to reach close to US$ 300 million revenue by 2026 end. Although bacteria causes sepsis on a large scale, the increase in sepsis is due to the gram-positive sepsis. Various studies carried on sepsis are showing that gram-positive bacteria accounts for maximum septic shock and severe sepsis cases. Moreover, the mortality rate due to gram-positive infection is high as compared to the gram-negative infection. Hence, therapeutic protocols are being undertaken to manage both gram-positive and gram-negative sepsis. Request Sample: https://www.factmr.com/connectus/sample?flag=S&rep_id=391 Table of Content 1. Global Economic Outlook 2. Global Sepsis Diagnostics Market - Executive Summary 3. Global Sepsis Diagnostics Market Overview 4. Global Sepsis Diagnostics Market Analysis and Forecast 2012-2026 To be Continue....... Considering the broad scope of the global sepsis diagnostics market, the report by Fact.MR provides key insights and segmentation analysis and forecast. The global sepsis diagnostics market is segmented into product type, method, pathogen, technology, and region. The segment-wise analysis also provides detailed country-wise forecast by taking into account all the key parameters of the global sepsis diagnostics market. The report’s last section comprises of d of 2026, North America is projected to exceed US$ 200 million revenue. Well-established healthcare infrastructure, the rise in adoption of advanced products is driving the growth of the market in the region. Moreover, septic poisoning is one of the leading causes of death in the U.S. Assays & Reagents to Emerge as the Top-Selling Product Sepsis is a severe illness triggered by body’s response to an infection. Factors that are resulting in the growth of sepsis diagnostics market are the rise in aging population, increasing incidences of hospital acquired infections and the growth in the development of innovative products and approvals of those products. Major market players are also increasingly investing in the research and development of new treatments, tests and interventions in order to detect, treat and prevent diseases. Depending on the symptoms, various tests are being performed including blood tests, laboratory tests, and imaging scans. Also, a lot of diagnostic tools are under the approval process and clearance by the Food and Drugs Administration (FDA). The report has also profiled leading companies in the global market for sepsis diagnostics, which will remain active through 2026. These include companies such as Biomérieux SA, Quidel Corporation, Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Luminex Corporation, Abbott Laboratories, Inc., T2 Biosystems, Inc., Roche Holdings AG (Roche Diagnostics Limited), Danaher Corporation (Beckman Coulter, Inc.), Qiagen NV, Siemens Healthineers, and Abionic SA. Like it? Share it!More by this author |